Associated Papers
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Coexistent PTEN and PIK3CA alterations hyperactivate mTORC1 signaling in endometrial cancers and cause their selective sensitivity to mTORC1 inhibition.
Solomon H et al.
Biorxiv : the Preprint Server for Biology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Novel interlock probe-driven ligation-mediated PCR platform for ultra-specific detection of low-frequency single-nucleotide variation.
Li X et al.
Talanta, 2026
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.
Li JJ et al.
Pathology, 2026
Targeting the protein-protein interaction between the CDC37 cochaperone and client kinases by an allosteric RAF dimer breaker.
Yu A et al.
The Journal of Biological Chemistry, 2026
Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.
Varty K et al.
Genes, Chromosomes & Cancer, 2026
Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.
Rustamov R et al.
Virchows Archiv : an International Journal of Pathology, 2026
Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy.
Htoo A et al.
Journal of the American Society of Cytopathology, 2026
RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.
Nindra U et al.
Cancer Treatment and Research Communications, 2026
KRAS mutation and its association with clinicopathological features of colorectal cancer patients in Africa: a systematic review and meta-analysis.
Kassaw AB et al.
Bmc Cancer, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.
Oh CR et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Hernandez S et al.
Lung Cancer (amsterdam, Netherlands), 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape.
Serafimidis I
Frontiers in Oncology, 2026
KRAS and MET Co-Mutation in One Lesion and EGFR Mutation in Another Lesion of Early-Stage Synchronous Multiple Lung Adenocarcinomas: A Case Report.
Ito T et al.
The Tohoku Journal of Experimental Medicine, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).
Wang SA et al.
Haematologica, 2025
Single-cell multi-omics characterize colorectal tumors, adjacent healthy tissue and matched (tumor) organoids identifying CRC-unique features.
Yu Z et al.
International Journal of Cancer, 2025
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Age-Related Multigene Analysis of Colorectal Cancer Using Next-Generation Sequencing.
Kozlowska-Geller M et al.
Cancers, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.
Navarro-Jiménez M et al.
Npj Precision Oncology, 2025
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
Haraguchi E et al.
International Journal of Cancer, 2025
TP53 c.730G > A pathogenic variant as a plausible candidate biomarker in pancreatic ductal adenocarcinoma patients from Karachi, pakistan: a retrospective cohort study.
Ali SMA et al.
Bmc Cancer, 2025
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Ianniello M et al.
Journal of Translational Medicine, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Hamza A et al.
British Journal of Cancer, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.
Aboelmaaty S et al.
Annals of Surgical Oncology, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Yan S et al.
Translational Lung Cancer Research, 2025
TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation.
Braun M et al.
Translational Lung Cancer Research, 2025
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
Hartner S et al.
Nature Communications, 2025
Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.
Shi X et al.
Journal of Advanced Research, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations.
Kojitani Y et al.
Oncology Letters, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025